{"id":"sofosbuvir-oral-product","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Anemia"},{"rate":"10-15","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1259059","moleculeType":"Small molecule","molecularWeight":"529.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a prodrug that is metabolized intracellularly to its active triphosphate form, which acts as a chain terminator when incorporated into the growing HCV RNA strand during replication. By inhibiting the NS5B polymerase, a critical enzyme for HCV genome replication, sofosbuvir prevents the virus from making copies of itself and establishing persistent infection.","oneSentence":"Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:40.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotypes 1-6, in combination with other direct-acting antivirals"}]},"trialDetails":[{"nctId":"NCT04075916","phase":"PHASE2","title":"A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-06-22","conditions":"End Stage Renal Disease","enrollment":201},{"nctId":"NCT06953479","phase":"PHASE4","title":"Implementing Low-Barrier HCV Treatment in a Jail Setting","status":"RECRUITING","sponsor":"Lifespan","startDate":"2025-06-11","conditions":"HEPATITIS C (HCV), Incarceration, Injection Drug Use","enrollment":40},{"nctId":"NCT05140941","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy","status":"RECRUITING","sponsor":"Catherine Anne Chappell","startDate":"2022-04-04","conditions":"Hepatitis C, Chronic, Pregnancy; Infection","enrollment":100},{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT03222531","phase":"PHASE2","title":"Expanding the Pool in Orthotopic Heart Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mary E. Keebler, MD","startDate":"2017-08-01","conditions":"Hepatitis C, Heart Transplant, Cardiac Transplant","enrollment":20},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT05248919","phase":"NA","title":"Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2023-06-01","conditions":"Hepatitis C","enrollment":318},{"nctId":"NCT03809533","phase":"PHASE2","title":"The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amit D Tevar, MD","startDate":"2019-05-29","conditions":"Kidney Transplantation, Hepatitis C","enrollment":30},{"nctId":"NCT03819322","phase":"PHASE2","title":"The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients","status":"COMPLETED","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2019-08-15","conditions":"Liver Transplant, Hepatitis C","enrollment":73},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT04382404","phase":"PHASE1","title":"Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir","status":"COMPLETED","sponsor":"Catherine Anne Chappell","startDate":"2020-10-22","conditions":"Hepatitis C, Chronic","enrollment":11},{"nctId":"NCT06180590","phase":"","title":"The Efficacy of Vosevi in Treating DAA-experienced Patients","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Guangzhou Medical University","startDate":"2023-02-28","conditions":"Chronic Hepatitis C, Medication Reaction","enrollment":200},{"nctId":"NCT03801707","phase":"PHASE2, PHASE3","title":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2019-03-22","conditions":"Kidney Transplant, Hepatitis C, HCV","enrollment":54},{"nctId":"NCT03903185","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-03-01","conditions":"Hepatitis C, Chronic, Hematologic Malignancy","enrollment":24},{"nctId":"NCT03118674","phase":"PHASE2","title":"Harvoni Treatment Porphyria Cutanea Tarda","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-09-06","conditions":"Porphyria Cutanea Tarda, Hepatitis C","enrollment":23},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT03057847","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Elizabeth Krans, MD","startDate":"2018-01-30","conditions":"Hepatitis C, Chronic, Opioid-use Disorder","enrollment":32},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT04695769","phase":"PHASE4","title":"Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-21","conditions":"Chronic Hepatitis C","enrollment":281},{"nctId":"NCT04112303","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-10-16","conditions":"Hepatitis C Virus Infection","enrollment":37},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT02951364","phase":"","title":"Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-12-05","conditions":"Hepatitis C Virus","enrollment":1081},{"nctId":"NCT03146741","phase":"PHASE1, PHASE2","title":"Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-16","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT03236506","phase":"PHASE2","title":"A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2018-01-19","conditions":"Hepatitis C","enrollment":129},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT05091008","phase":"PHASE2","title":"Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children","status":"COMPLETED","sponsor":"Mansoura University Children Hospital","startDate":"2018-03-01","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT03312023","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-02-01","conditions":"Hepatitis B","enrollment":21},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT03818308","phase":"PHASE2","title":"Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2019-05-28","conditions":"Hepatitis C, Acute Hepatitis C","enrollment":20},{"nctId":"NCT02133131","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-13","conditions":"Hepatitis C","enrollment":143},{"nctId":"NCT04358523","phase":"PHASE1","title":"A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2020-03-20","conditions":"Healthy","enrollment":50},{"nctId":"NCT02825212","phase":"PHASE2, PHASE3","title":"Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-02","conditions":"Hepatitis C, Cryoglobulinemia","enrollment":10},{"nctId":"NCT04498936","phase":"PHASE4","title":"Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-07-15","conditions":"COVID","enrollment":240},{"nctId":"NCT03022981","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-01-26","conditions":"Hepatitis C Virus Infection","enrollment":216},{"nctId":"NCT02533427","phase":"PHASE1","title":"Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-10-29","conditions":"HCV Infection","enrollment":15},{"nctId":"NCT02468648","phase":"PHASE2","title":"Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2015-06-09","conditions":"Chronic Hepatitis C","enrollment":72},{"nctId":"NCT02613871","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"Hepatitis C Virus Infection","enrollment":111},{"nctId":"NCT03036852","phase":"PHASE2","title":"Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-03-22","conditions":"Chronic Hepatitis C","enrollment":59},{"nctId":"NCT02378935","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-17","conditions":"Hepatitis C Virus Infection","enrollment":205},{"nctId":"NCT02021656","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-12-10","conditions":"Chronic HCV Infection","enrollment":384},{"nctId":"NCT02378961","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-16","conditions":"Hepatitis C Virus Infection","enrollment":128},{"nctId":"NCT03036839","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-06-27","conditions":"Hepatitis C Virus Infection","enrollment":95},{"nctId":"NCT02994056","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-01-23","conditions":"Hepatitis C Virus Infection","enrollment":32},{"nctId":"NCT02249182","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-11-05","conditions":"Hepatitis C Virus Infection","enrollment":226},{"nctId":"NCT02868242","phase":"PHASE2","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-28","conditions":"Hepatitis C Virus Infection","enrollment":19},{"nctId":"NCT03549312","phase":"PHASE4","title":"Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy","status":"UNKNOWN","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2018-02-01","conditions":"HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence","enrollment":25},{"nctId":"NCT04169464","phase":"PHASE4","title":"The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy","status":"UNKNOWN","sponsor":"MTI University","startDate":"2019-04-01","conditions":"Egyptian Patients, HCV Treatment, Kidney Function","enrollment":200},{"nctId":"NCT03207399","phase":"PHASE4","title":"Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment","status":"TERMINATED","sponsor":"Duke University","startDate":"2017-09-15","conditions":"Hepatitis C, Chronic, Lung Transplant","enrollment":1},{"nctId":"NCT04063839","phase":"","title":"HCV Treatment in a Low-threshold Clinic","status":"UNKNOWN","sponsor":"University Hospital, Akershus","startDate":"2015-01","conditions":"Hepatitis C, Substance Use Disorders","enrollment":300},{"nctId":"NCT02347345","phase":"PHASE4","title":"Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2016-11-15","conditions":"Hepatitis C","enrollment":34},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03961828","phase":"PHASE4","title":"Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus","status":"COMPLETED","sponsor":"Tanta University","startDate":"2017-10-01","conditions":"Beta-Thalassemia, Hepatitis C","enrollment":50},{"nctId":"NCT02760355","phase":"NA","title":"Extrahepatic Insulin Resistance in Chronic Hepatitis C","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Insulin Resistance","enrollment":17},{"nctId":"NCT03118843","phase":"PHASE3","title":"Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-04-25","conditions":"Hepatitis C Virus Infection","enrollment":31},{"nctId":"NCT03074331","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-03-23","conditions":"Hepatitis C Virus Infection","enrollment":130},{"nctId":"NCT02607735","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C","enrollment":416},{"nctId":"NCT02639247","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":333},{"nctId":"NCT02607800","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-16","conditions":"Hepatitis C","enrollment":943},{"nctId":"NCT02639338","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":220},{"nctId":"NCT02336139","phase":"PHASE2","title":"A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-03-16","conditions":"Hepatitis C","enrollment":103},{"nctId":"NCT02996682","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-12-26","conditions":"Hepatitis C Virus Infection","enrollment":102},{"nctId":"NCT02536313","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-07-29","conditions":"Hepatitis C Virus Infection","enrollment":49},{"nctId":"NCT02591277","phase":"","title":"Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-30","conditions":"Hepatitis C","enrollment":3294},{"nctId":"NCT02728206","phase":"PHASE2","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-06-12","conditions":"Hepatitis C Virus Infection","enrollment":9},{"nctId":"NCT02671500","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-19","conditions":"Hepatitis C Virus Infection","enrollment":375},{"nctId":"NCT02717949","phase":"PHASE4","title":"Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-02-25","conditions":"Liver Disease","enrollment":1},{"nctId":"NCT02781558","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-29","conditions":"Hepatitis C Virus Infection","enrollment":204},{"nctId":"NCT02350569","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-05-22","conditions":"Hepatitis C Virus Infection","enrollment":17},{"nctId":"NCT01987453","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"HCV Infection","enrollment":100},{"nctId":"NCT02081079","phase":"PHASE2","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-03","conditions":"Chronic Genotype 4 HCV, Chronic Genotype 5 HCV","enrollment":85},{"nctId":"NCT02251717","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-10-14","conditions":"Hepatitis C Virus Infection","enrollment":114},{"nctId":"NCT02010255","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-01","conditions":"Chronic HCV Infection","enrollment":334},{"nctId":"NCT01924949","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-07","conditions":"Hepatitis C","enrollment":5},{"nctId":"NCT02301936","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-03-02","conditions":"Hepatitis C Virus Infection","enrollment":10},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273},{"nctId":"NCT02487030","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-09-07","conditions":"Hepatitis C Virus Infection","enrollment":255},{"nctId":"NCT02201953","phase":"PHASE3","title":"Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":558},{"nctId":"NCT02226549","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":47},{"nctId":"NCT02600351","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT01938430","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09","conditions":"Chronic HCV Infection","enrollment":339},{"nctId":"NCT01826981","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-04","conditions":"Chronic Hepatitis C","enrollment":359},{"nctId":"NCT02457611","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06","conditions":"Hepatitis C Infection With HIV Co-Infection","enrollment":26},{"nctId":"NCT01726517","phase":"PHASE2","title":"Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10","conditions":"Chronic Hepatitis C Virus","enrollment":100},{"nctId":"NCT02346721","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-23","conditions":"Hepatitis C Virus Infection","enrollment":111},{"nctId":"NCT02219685","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08","conditions":"Hepatitis C Virus Infection","enrollment":40},{"nctId":"NCT01965535","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"HCV Infection","enrollment":155},{"nctId":"NCT02413593","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-04","conditions":"Hepatitis C Virus Infection","enrollment":111},{"nctId":"NCT02300103","phase":"PHASE2","title":"Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-01","conditions":"Hepatitis C Virus Infection","enrollment":69},{"nctId":"NCT02722837","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-04","conditions":"Hepatitis C Virus Infection","enrollment":119},{"nctId":"NCT01768286","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-01","conditions":"Chronic Hepatitis C Virus","enrollment":441},{"nctId":"NCT02472886","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-17","conditions":"Hepatitis C Virus Infection","enrollment":153},{"nctId":"NCT02480712","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-07-01","conditions":"Hepatitis C Virus Infection","enrollment":107},{"nctId":"NCT02073656","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-02","conditions":"Hepatitis C Virus, HIV","enrollment":335},{"nctId":"NCT01701401","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-09","conditions":"Chronic Hepatitis C Virus","enrollment":870},{"nctId":"NCT02738333","phase":"PHASE3","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-12","conditions":"Hepatitis C Virus Infection","enrollment":239},{"nctId":"NCT01851330","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05","conditions":"Chronic Hepatitis C Virus","enrollment":647}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gratisovir"],"phase":"marketed","status":"active","brandName":"Sofosbuvir Oral Product","genericName":"Sofosbuvir Oral Product","companyName":"MTI University","companyId":"mti-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir is a small molecule inhibitor of RNA-directed RNA polymerase, classified as an INHIBITOR. It is used to treat conditions such as Chronic Hepatitis C, Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation, and HIV-1 Infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}